QuidelOrtho Corp 2026年季度报告

FORM10-Q____________________________________________________________________________ ☒QUARTERLY REPORT PURSUANT TO SECTION13 OR15(d)OFTHE SECURITIESEXCHANGE ACT OF 1934 For the quarterly period ended March29, 2026or TRANSITION REPORT PURSUANT TO SECTION13 OR15(d)OFTHE SECURITIESEXCHANGE ACT OF 1934 For the transition period fromtoCommission File Number: 001-41409____________________________________________________________________________ QUIDELORTHO CORPORATION (Exact name of registrant as specified in its charter)____________________________________________________________________________ (858)552-1100(Registrant’s telephone number, including area code)Not Applicable(Former name, former address and former fiscal year, if changed since last report) Indicate by check mark whether the registrant: (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities Exchange Act of1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subject to such filingrequirements for the past 90days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, oran emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐ INDEX PARTI—FINANCIAL INFORMATIONITEM1. Financial Statements (unaudited)Consolidated Balance Sheets as of March 29, 2026 and December 28, 2025Consolidated Statements of Loss for the three months ended March 29, 2026 and March 30, 2025Consolidated Statements of Comprehensive Loss for the three months ended March 29, 2026 and March 30, 2025Consolidated Statements of Stockholders’ Equity for the three months ended March 29, 2026 and March 30, 2025Consolidated Statements of Cash Flows for the three months ended March 29, 2026 and March 30, 2025Notes to Consolidated Financial StatementsITEM2. Management’s Discussion and Analysis of Financial Condition and Results of OperationsITEM3. Quantitative and Qualitative Disclosures About Market RiskITEM4. Controls and ProceduresPARTII—OTHER INFORMATIONITEM1. Legal ProceedingsITEM1A. Risk FactorsITEM2. Unregistered Sales of Equity Securities and Use of ProceedsITEM3. Defaults Upon Senior SecuritiesITEM4. Mine Safety DisclosuresITEM5. Other InformationITEM6. ExhibitsSummary of Abbreviated TermsSignatures QUIDELORTHO CORPORATIONCONSOLIDATED BALANCE SHEETS(Unaudited)(In millions, except par value) QUIDELORTHO CORPORATIONCONSOLIDATED STATEMENTS OF LOSS(Unaudited)(In millions, except per share data) QUIDELORTHO CORPORATIONCONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(Unaudited)(In millions) See accompanying notes. QUIDELORTHO CORPORATIONCONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(Unaudited)(In millions) QUIDELORTHO CORPORATIONCONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)(In millions) QuidelOrtho Corporation Notes to Consolidated Financial Statements (Unaudited) Note 1. Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited Consolidated Financial Statements of QuidelOrtho Corporation and its subsidiaries (the “Company” or“QuidelOrtho”) have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q andArticle 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financialstatements. In the opinion of management, all adjustments considered necessary for a fair presentation (consisting of normal recurringaccruals) have been included. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report for definitions of terms usedthroughout this Quarterly Report. The information at March29, 2026, and for the three months ended March 29, 2026 and March 30, 2025, is unaudited. For furtherinformation, refer to the Company’s Consolidated Financial Statements and notes thereto for fiscal year ended December28, 2025 includedin QuidelOrtho’s Annual Report. Operating results for any quarter are historically seasonal in nature and are not necessarily indicative of theresults expected for the full year. The Company follows the concept of a fiscal year that ends on the Sunday nearest to the end of the month of December, and fiscal quartersthat end on the Sunday nearest to the end of the months of March, June and September. For 2026 and 2025, the Company’s fiscal year willend or has ended on Jan